Gerresheimer stock weighs sales growth against margin pressure
Published on 11/13/2026 at 12:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth Meets Margin Pressure
- Gerresheimer lifted third-quarter revenue by 8 percent to EUR 605 million, while adjusted EBITDA held at EUR 103 million.
- Inventory reductions and weaker performance in Tubular Glass Europe and Moulded Glass cut the nine-month adjusted EBITDA margin to 15.9 percent.
- Management expects a stronger fourth quarter and plans to publish final third-quarter figures in December 2026.
Gerresheimer reported stronger third-quarter sales but continued margin pressure in preliminary results released on October 30, 2026. The company said revenue including business units currently in the sales process rose 8 percent year over year to EUR 605 million, while adjusted EBITDA reached EUR 103 million compared with EUR 106 million in the adjusted prior-year quarter. The figures were published in the company's Q3 results release.
Revenue Growth, Lower Profitability
For the first nine months, revenue stood at EUR 1.7 billion, broadly level with the adjusted prior-year period. Adjusted EBITDA declined to EUR 272 million from EUR 331 million. Gerresheimer attributed the shortfall to inventory reductions and weaker performance in the Tubular Glass Europe and Moulded Glass businesses.
The adjusted EBITDA margin fell to 17.1 percent in the quarter from 19.0 percent a year earlier. For the first nine months, the margin was 15.9 percent compared with 19.4 percent in the adjusted prior-year period. The figures indicate that higher demand has not yet translated into comparable profitability across the group.
Drug Delivery Supports Growth
Containment and Delivery Systems remained the main growth engine. Nine-month revenue in the division rose to EUR 917 million from EUR 876 million, while adjusted EBITDA increased to EUR 211 million from EUR 194 million. Its third-quarter adjusted EBITDA margin reached 24.5 percent, up from 22.3 percent a year earlier, as demand for drug delivery devices supported the capacity expansion carried out in recent years.
Primary Injectable Solutions showed signs of stabilization in the third quarter, although its nine-month figures remained below the prior year. Third-quarter revenue reached EUR 123 million, up from EUR 114 million, while adjusted EBITDA was EUR 15 million against EUR 19 million. In Moulded Glass, quarterly revenue rose to EUR 169 million from EUR 165 million, but adjusted EBITDA fell to EUR 17 million from EUR 29 million as inventory reductions reduced capacity utilization.
Stronger Fourth Quarter Ahead
Gerresheimer expects a stronger fourth quarter with further earnings improvement, in line with its guidance. CFO Wolf Lehmann said the company had improved its financial position after completing the Centor sale in October. Gerresheimer is also preparing the sale of its Primary Packaging Plastics business, which it expects to close in the first quarter of 2027. The company said a comprehensive refinancing is another upcoming milestone.
Gerresheimer stock traded at 31.41 euros on Lang & Schwarz at 12:20 CET on Friday, November 13, 2026.
Gerresheimer stock at a glance
- Company: Gerresheimer AG
- ISIN: DE000A0LD6E6
- Ticker: GXI.DE
- Trading venue: Lang & Schwarz
- Price: 31.41 euros at 12:20 CET on November 13, 2026
Investors can follow broader German market developments in Current market reports.
Further company updates and analysis are available in More news and analyses on Gerresheimer stock.
